Literature DB >> 22576792

Hemophagocytic lymphohistiocytosis complicated by central nervous system lesions in a patient with dermatomyositis: a case presentation and literature review.

Hiroyuki Yamashita1, Yuko Matsuki, Arisa Shimizu, Makoto Mochizuki, Yuko Takahashi, Toshikazu Kano, Akio Mimori.   

Abstract

We report a case of dermatomyositis (DM) and hemophagocytic lymphohistiocytosis (HLH) complicated by central nervous system (CNS) lesions and review eight literature cases of DM and HLH. A 17-year-old woman, admitted to our hospital because of severe muscle weakness and high fever, was diagnosed with DM based on elevated serum levels of muscle enzymes and a typical skin rash. Pancytopenia, high serum ferritin and soluble interleukin (IL)-2 receptor, and hepatosplenomegaly were also noted. Bone-marrow examination was negative for hemophagocytosis. Steroid therapy combined with immunoglobulin i.v. was ineffective against the DM, pancytopenia, hepatic dysfunction, and hyperferritinemia. On the 27th hospital day, seizures and acute respiratory failure occurred. In the course of improving muscle enzyme levels after starting adjunctive treatment with cyclosporine, the patient suffered disturbed consciousness, dyskinesia, and tremor. Brain magnetic resonance imaging (MRI) revealed T2 hyperintense lesions in the pons. Additional cyclophosphamide pulse therapy successfully decreased serum ferritin. Unfortunately, the diffuse alveolar damage (DAD) confirmed by biopsy progressed and the patient died. Autopsy findings revealed DAD throughout both lungs, HLH liver lesions, and a hemorrhagic necrotic lesion of the pons in the brain. Even when pathological examination yields no findings of hemophagocytosis, it is important to comprehensively and rapidly diagnose HLH based on the clinical picture. Because DM complicated by HLH may be associated with abnormal production of cytokines and systemic autoimmune responses, it may be necessary to immediately administer additional immunosuppressive therapy. We describe and discuss the extraordinary, severe form of DM in our patient, along with cases in the literature.

Entities:  

Mesh:

Year:  2012        PMID: 22576792     DOI: 10.1007/s10165-012-0661-6

Source DB:  PubMed          Journal:  Mod Rheumatol        ISSN: 1439-7595            Impact factor:   3.023


  6 in total

Review 1.  Macrophage activation syndrome in juvenile dermatomyositis: a systematic review.

Authors:  Dimitri Poddighe; Kaisar Dauyey
Journal:  Rheumatol Int       Date:  2019-09-16       Impact factor: 2.631

2.  Hemophagocytic lymphohistiocytosis with leukoencephalopathy in a patient with dermatomyositis accompanied with peripheral T-cell lymphoma: a case report.

Authors:  Satoru Teshigawara; Yoshinori Katada; Yuichi Maeda; Maiko Yoshimura; Eriko Kudo-Tanaka; Soichiro Tsuji; Yoshinori Harada; Masato Matsushita; Shiro Ohshima; Kotaro Watanabe; Takahiro Kumode; Yoshihiko Hoshida; Yukihiko Saeki
Journal:  J Med Case Rep       Date:  2016-08-02

3.  Fulminant systemic capillary leak syndrome due to C1 inhibitor deficiency complicating acute dermatomyositis: a case report.

Authors:  Ilse Gradwohl-Matis; Romana Illig; Hermann Salmhofer; Daniel Neureiter; Andreas Brunauer; Martin W Dünser
Journal:  J Med Case Rep       Date:  2014-01-27

Review 4.  MDA5-positive dermatomyositis: an uncommon entity in Europe with variable clinical presentations.

Authors:  Anna Radice; Boaz Palterer; Paola Parronchi; Francesco Liotta; Cristina Scaletti
Journal:  Clin Mol Allergy       Date:  2015-11-09

5.  Hemophagocytic Syndrome Complicated with Dermatomyositis Controlled Successfully with Infliximab and Conventional Therapies.

Authors:  Yoji Komiya; Tetsuya Saito; Fumitaka Mizoguchi; Hitoshi Kohsaka
Journal:  Intern Med       Date:  2017-12-01       Impact factor: 1.271

6.  Hemophagocytic lymphohistiocytosis complicated by multiorgan failure: A case report.

Authors:  Federica Lovisari; Valeria Terzi; Monica G Lippi; Paolo R Brioschi; Roberto Fumagalli
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.